European thyroid journal
IF
3.38
Papers
469
Papers 533
1 page of 54 pages (533 results)
Newest
#1Yuwei LiuH-Index: 2
#2Shengcai WangH-Index: 5
Last. Yongli GuoH-Index: 25
view all 0 authors...
Source
#1Tomasz BednarczukH-Index: 23
#2Thomas Heiberg BrixH-Index: 39
Last. George J. KahalyH-Index: 64
view all 0 authors...
Source
Source
Source
Source
#1Giovanni MauriH-Index: 28
#2Laszlo HegedüsH-Index: 89
Last. Enrico PapiniH-Index: 51
view all 11 authors...
2 CitationsSource
Source
#1Suvi TurunenH-Index: 1
Last. Eila SuvantoH-Index: 11
view all 6 authors...
Source
#1Yuan LiH-Index: 2
#2Chenxu ZhaoH-Index: 2
view all 13 authors...
Objective Thyroglobulin antibodies (TgAb), principally comprising immunoglobulin G (IgG), are frequently found in healthy individuals. Previously, we showed that the glycosylation levels of TgAb IgG differed across various thyroid diseases, suggesting an important role of glycosylation on antibodies in the pathogenesis of thyroid diseases. Since IgG1 and IgG4 are the primary TgAb IgG subclasses, this study aimed to investigate the glycosylation of TgAb IgG1 and IgG4 subclasses in thyroid disease...
Source
Introduction Tyrosine kinase inhibitors (TKIs) have been used in patients with advanced medullary thyroid carcinoma (MTC); however, data on their effectiveness and safety are limited. The aim of this systematic review and meta-analysis was to document clinical response and toxicities of TKIs in advanced MTC. Methods We systematically searched major databases for articles or abstracts on TKI use in MTC patients until May 2018. Objective response (OR), defined as the sum of complete + partial resp...
Source
12345678910
Top fields of study
Endocrinology
Pathology
Thyroid cancer
Thyroid carcinoma
Thyroid
Medicine